HALO logo
halo search icon
NWRN
Newron Pharmaceuticals S.p.A.

NWRN · Newron Pharmaceuticals S.p.A.

7.45

CHF
-0.27 (-3.497%)
07/10/2026 12:00:00 AM
Price change (7D)

Unlock stock Insights

Create a free account to unlock price targets, recommendations, and commentary.

Overview

Market Cap

Fr172.46M

PE

0.00

EV/EBITDA

N/A

DIV Yield

0%

Payout Ratio

0%

MQV Rating

5Very Weak

As at 07/10/2026 12:00:00 AM

Price Chart

Description

Newron Pharmaceuticals SpA operates as a biopharmaceutical company. It focuses on the development of novel therapies for patients with diseases of the central and peripheral nervous system. The firm's products include Xadago (safinamide), Evenamide (NW-3509) and Ralfinamide. The company was founded by Luca Benatti, Ruggero Fariello and Patricia Salvati in 1999 and is headquartered in Bresso, Italy.

  • All-Companies
  • All-Consensus
  • HALO 200
  • HALO All
  • HALO Consensus Value
  • HALO Small

Key Fundamentals

EPS 3 yr Growth

-32.30%

EBITDA Margin

-23.70%

Operating Cashflow

€32m

Free Cash Flow Return

231.50%

ROIC

-94.70%

Interest Coverage

-1.00

Quick Ratio

0.80

Performance

52 weeks range

Low 7.61 - 31.85

Trade Value (12mth)

US$531,977.00

1 week

-22.37%

1 month

-32.45%

YTD

-68.16%

1 year

-36.36%

All time high

80.25

Additional Data

Shares Outstanding (Fully Diluted)

21m

HALO Sector

Healthcare

Next Company Report Date

16-Mar-27

Next Ex Dividend Date

N/A

Next Dividend Pay Date

N/A

Reporting Currency

EUR

Short Sell (% of issue)

0.00

Consensus

Lock Icon

Unlock full consensus

Consensus score

Lock Icon/10

Recommendation

Buy

Target price

Lock Icon

Deviation

Lock Icon

Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

Mqv

Very Weak

Garp

Very Weak

Mqv Small

Very Weak

Momentum

Price

Very Weak

Earnings

Very Weak

Growth

Earnings

Very Weak

Dividends

Very Weak

Quality

Capital Efficiency

Neutral

Balance Sheet

Neutral

Valuation

Lock Icon

Unlock full dataset

Value

Lock Icon

Consensus

Lock Icon

Yield

Lock Icon

News & Announcements

No announcements available.

Key Stakeholders

NameTitle
Tobias SchererIndividual
European Investment BankGovernment
Newron Pharmaceuticals SpAPublic Company

See beyond the curve.

One solution for research, investing and model portfolio management.
Start FREE Trial
Want to learn more?Frequently asked questions.
1
What is the current share price of Newron Pharmaceuticals S.p.A. (NWRN:SWX)?
Halo FAQ
The current share price of Newron Pharmaceuticals S.p.A. (NWRN:SWX) is CHFCHF7.45.
2
What is the 52-week high share price for Newron Pharmaceuticals S.p.A. (NWRN:SWX)?
Halo FAQ
The 52-week high share price for Newron Pharmaceuticals S.p.A. (NWRN:SWX) is CHFCHF31.85.
3
What is the 52-week low share price for Newron Pharmaceuticals S.p.A. (NWRN:SWX)?
Halo FAQ
The 52-week low share price for Newron Pharmaceuticals S.p.A. (NWRN:SWX) is CHFCHF7.61.
4
What is the dividend yield for Newron Pharmaceuticals S.p.A. (NWRN:SWX)?
Halo FAQ
Newron Pharmaceuticals S.p.A. (NWRN:SWX) does not pay a dividend.
5
What was Newron Pharmaceuticals S.p.A. (NWRN:SWX) last dividend payment?
Halo FAQ
Newron Pharmaceuticals S.p.A. (NWRN:SWX) does not pay a dividend.
6
What is the franking level for Newron Pharmaceuticals S.p.A. (NWRN:SWX)?
Halo FAQ
Newron Pharmaceuticals S.p.A. (NWRN:SWX) has a franking level of 0.00%.
7
In which sector is Newron Pharmaceuticals S.p.A. (NWRN:SWX) classified?
Halo FAQ
Newron Pharmaceuticals S.p.A. (NWRN:SWX) is classified in the Healthcare.